Bristol-myers Squibb Compnay

Theracos, Inc.

Theracos Sub, LLC

Sloan-kettering Institute for Cancer Research

Jacques Y Roberge

Brian Seed

Binhua Lv

Ge Xu

Baihua Xu

R Michael Lawrence

Mark E Salvati

Richard A Rampulla

Wu Yang

Jennifer X Qiao

Tammy C Wang

Yan Feng

Yuanwei Chen

Timur Gungor

Jiyan Du

James R Corte

Yufeng Wang

Qian Liu

Timothy F Herpin

Yanli Song

Michael J Hadd

Robert P Rehfuss

Yuelin Wu

Shengbin Li

Huawei Cheng

Congna Wang

Mengzhuang Cai

James Aaron Balog

Ramesh N Patel

James A Johnson

Heather J Finlay

John E Lloyd

Steven H Spergel

Raj N Misra

Hai-Yun Xiao

Ronald L Hanson

Zulan Pi

Michael Matthew Miller

Lalgudi S Harikrishnan

Ji Jiang

Toomas Mitt

Muthoni G Kamau

Wenying Li

Dacia A Pickering

Sören Giese

Xinxing Tang

Aberra Fura

Jian Zhang

Michael A Poss

Bang-Chi Chen

Charles G Clark

George C Morton

Patrick Y S Lam

Rejean Ruel

Carl Thibeault

Hannguang J Chao

Alexandre L'Heureux

David P Rotella

Jianqing Li

Huji Tuerdi

Gilles Bouthillier

Dora M Schnur

Yalei Liu

Carine Vaxelaire

Baohu Liu

Lili Zhang

Samuel J Danishefsky

Katerina Leftheris

Jagabandhu Das

Ping Chen

Min Xu

Ashvinikumar V Gavai

William John Pitts

Wayne D Vaccaro

Joel C Barrish

Derek J Norris

Edwin J Iwanowicz

John K Dickson

Joseph Barbosa

John Kenneth Dickson, Jr

Jiajia Dong

Gary L Schieven

Ramesh Padmanabha

Kun Peng

Roy J Vaz

Michael R Lawrence

Xenia Beebe

Binhua Xu

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Crystalline form of benzylbenzene SGLT2 inhibitor

Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.

Preparation of hydroxy-benzylbenzene derivatives

Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.

Process for the preparation of benzylbenzene SGLT2 inhibitors

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions that are affected by SGLT inhibition.

Deuterated benzylbenzene derivatives and methods of use

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

Benzylbenzene derivatives and methods of use

Compounds of formula Ia and Ib wherein A, B, C and Rare described herein.

Heterocyclic CETP inhibitors

Compounds of formula Ia and Ib and wherein A, B, C and Rare described herein.

The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Yreceptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Yreceptor activity.

[object Object]

Growing community of inventors

Princeton, NJ, United States of America

Jacques Y Roberge